Evaluation of PTEN loss and PIK3CA mutations and their correlation with efficacy of trastuzumab treatment in HER2-positive metastatic breast cancer: A retrospective study (KBC-SG 1001)

Author： Nishimura  

Publisher： Spandidos Publications

ISSN： 2049-9469

Source： Molecular and Clinical Oncology, Vol.1, Iss.1, 2013-01, pp. : 47-52

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas

By Lerma Enrique  

Virchows Archiv, Vol. 453, Iss. 2, 2008-08 ,pp. : 133-139

Springer Publishing Company

Access to resources Recommend Favorite

Extended trastuzumab therapy improves the survival of HER2positive breast cancer patients following surgery and radiotherapy for brain metastases

By                            

Molecular and Clinical Oncology, Vol. 1, Iss. 6, 2013-01 ,pp. : 995-1001

Spandidos Publications

Access to resources Recommend Favorite

Antiangiogenic Agents in the Treatment of HER2-Negative Metastatic breast Cancer: A Brief Review

By  

Current Angiogenesis, Vol. 3, Iss. 2, 2014-07 ,pp. : 73-79

Bentham Science Publishers

Access to resources Recommend Favorite

Prognostic value of PIK3CA and phosphorylated AKT expression in ovarian cancer

By Woenckhaus Joachim   Steger Klaus   Sturm Klaus   Münstedt Karsten   Franke Folker   Fenic Irina  

Virchows Archiv, Vol. 450, Iss. 4, 2007-04 ,pp. : 387-395

Springer Publishing Company

Access to resources Recommend Favorite

Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer

By Tozuka  

Molecular and Clinical Oncology, Vol. 1, Iss. 1, 2013-01 ,pp. : 93-99

Spandidos Publications

Access to resources Recommend Favorite